Apollo Endosurgery Inc
F:HQ8F
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Apollo Endosurgery Inc
Accrued Liabilities
Apollo Endosurgery Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apollo Endosurgery Inc
F:HQ8F
|
Accrued Liabilities
$12.4m
|
CAGR 3-Years
22%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Accrued Liabilities
$3.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
13%
|
CAGR 10-Years
10%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Accrued Liabilities
$1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
|
Stryker Corp
NYSE:SYK
|
Accrued Liabilities
$4.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Accrued Liabilities
$7.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Accrued Liabilities
$1.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
18%
|
CAGR 10-Years
18%
|
|
Apollo Endosurgery Inc
Glance View
Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. The company is headquartered in West Lake Hills, Texas and currently employs 107 full-time employees. The company went IPO on 2005-04-21. The firm develops and distributes devices that are used by surgeons and gastroenterologists for various procedures related to gastrointestinal conditions including closure of gastrointestinal defects, managing gastrointestinal complications and the treatment of obesity. The firm's products include the OverStitch Endoscopic Suturing System, which enables advanced endoscopic procedures from within the Gastrointestinal tract, or endolumenally, by allowing physicians to suture, especially full-thickness, and secure the approximation of tissue. The X-Tack Endoscopic HeliX Tacking System is a suture-based device designed specifically for closing and healing defects in the lower gastrointestinal tract. The Orbera Intragastric Balloon System is a non-surgical alternative for interventional weight loss.
See Also
What is Apollo Endosurgery Inc's Accrued Liabilities?
Accrued Liabilities
12.4m
USD
Based on the financial report for Dec 31, 2022, Apollo Endosurgery Inc's Accrued Liabilities amounts to 12.4m USD.
What is Apollo Endosurgery Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
19%
Over the last year, the Accrued Liabilities growth was 25%. The average annual Accrued Liabilities growth rates for Apollo Endosurgery Inc have been 22% over the past three years , 11% over the past five years , and 19% over the past ten years .
